Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the future role of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of multiple myeloma. Prof. Einsele talks on the efficacy and tolerability of CAR-T in heavily pretreated patients, commenting on high response rates and complete response rates, and the potential of CAR-T therapy to be a cure for myeloma if used in earlier settings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.